{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T02:17:15Z","timestamp":1778033835269,"version":"3.51.4"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["FT190100218"],"award-info":[{"award-number":["FT190100218"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["DE220100456"],"award-info":[{"award-number":["DE220100456"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1163961"],"award-info":[{"award-number":["1163961"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1171459"],"award-info":[{"award-number":["APP1171459"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"publisher","award":["Monash Graduate Scholarship"],"award-info":[{"award-number":["Monash Graduate Scholarship"]}],"id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40263-025-01169-5","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T03:58:29Z","timestamp":1741233509000},"page":"499-512","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Early High-Risk Opioid Prescribing and Persistent Opioid Use in Australian Workers with Workers\u2019 Compensation Claims for Back and Neck Musculoskeletal Disorders or Injuries: A Retrospective Cohort Study"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9205-9442","authenticated-orcid":false,"given":"Yonas Getaye","family":"Tefera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Di Donato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Collie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"issue":"1","key":"1169_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/bcp.12937","volume":"82","author":"EA Karanges","year":"2016","unstructured":"Karanges EA, Blanch B, Buckley NA, Pearson SA. Twenty-five years of prescription opioid use in Australia: a whole-of-population analysis using pharmaceutical claims. Br J Clin Pharmacol. 2016;82(1):255\u201367.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1169_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/10826084.2018.1517175","volume":"54","author":"LE Dayer","year":"2019","unstructured":"Dayer LE, Painter JT, McCain K, King J, Cullen J, Foster HR. A recent history of opioid use in the US: three decades of change. Subst Use Misuse. 2019;54(2):331\u20139.","journal-title":"Subst Use Misuse"},{"key":"1169_CR3","doi-asserted-by":"crossref","unstructured":"Spencer MR, Mini\u00f1o AM, Warner M. Drug overdose deaths in the United States, 2001\u20132021. 2022.","DOI":"10.15620\/cdc:122556"},{"key":"1169_CR4","unstructured":"Australian Government Department of Health and Aged Care, The pharmaceutical benefit scheme. Revised opioids PBS listings from 1 June 2020 for the management of severe disabling pain. https:\/\/www.pbs.gov.au\/news\/2020\/05\/opioids-factsheet-files\/opioids-factsheet-2020-v3.pdf. Accessed 15 Nov 2024."},{"key":"1169_CR5","doi-asserted-by":"crossref","unstructured":"Jayawardana S, Forman R, Johnston-Webber C, Campbell A, Berterame S, de Joncheere C, et al. Global consumption of prescription opioid analgesics between 2009\u20132019: a country-level observational study. EClinicalMedicine. 2021;42:101198","DOI":"10.1016\/j.eclinm.2021.101198"},{"key":"1169_CR6","unstructured":"Australian Government Department of Health and Aged Care, The Pharmaceutical Benefit Scheme. Impact of regulatory reforms on utilisation of opioids: Drug utilisation sub-committee (DUSC); June 2023. https:\/\/www.pbs.gov.au\/industry\/listing\/participants\/public-release-docs\/2023-06\/opioid-regulatory-reform-impact-review-DUSC-PRD-2023-06.pdf. Accessed 15 Nov 2024."},{"key":"1169_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104053","volume":"117","author":"S Nielsen","year":"2023","unstructured":"Nielsen S, Picco L, Russell G, Pearce C, Andrew NE, Lubman DI, et al. Changes in opioid and other analgesic prescribing following voluntary and mandatory prescription drug monitoring program implementation: a time series analysis of early outcomes. Int J Drug Policy. 2023;117:104053.","journal-title":"Int J Drug Policy"},{"key":"1169_CR8","unstructured":"Penington Institute. Australia\u2019s Annual Overdose Report 2024. Melbourne: Penington Institute. 2024. https:\/\/www.penington.org.au\/wp-content\/uploads\/2024\/08\/PEN_Annual-Overdose-Report-2024.pdf. Accessed 6 Dec 2024."},{"key":"1169_CR9","volume-title":"Trends in overdose and other drug-induced deaths in Australia, 2003\u20132022","author":"A Chrzanowska","year":"2024","unstructured":"Chrzanowska A, Man N, Sutherland R, Degenhardt L, Peacock A. Trends in overdose and other drug-induced deaths in Australia, 2003\u20132022. Sydney: National Drug and Alcohol Research Centre, UNSW Sydney; 2024."},{"key":"1169_CR10","volume-title":"Trends in drug-related hospitalisations in Australia, 2002\u20132022","author":"A Chrzanowska","year":"2024","unstructured":"Chrzanowska A, Sutherland R, Degenhardt L, Peacock A. Trends in drug-related hospitalisations in Australia, 2002\u20132022. Sydney: National Drug and Alcohol Research Centre, UNSW Sydney; 2024."},{"key":"1169_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.06.035","volume":"205","author":"A Roxburgh","year":"2019","unstructured":"Roxburgh A, Hall WD, Gisev N, Degenhardt L. Characteristics and circumstances of heroin and pharmaceutical opioid overdose deaths: comparison across opioids. Drug Alcohol Depend. 2019;205: 107533.","journal-title":"Drug Alcohol Depend"},{"key":"1169_CR12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.31128\/AJGP-06-19-4967","volume":"49","author":"F Armstrong","year":"2020","unstructured":"Armstrong F, Arunogiri S, Frei M, Lubman D. The six Rs of managing high-risk opioid prescribing. Aust J Gen Practitioners. 2020;49:116\u201320.","journal-title":"Aust J Gen Practitioners"},{"issue":"2","key":"1169_CR13","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s11096-020-01155-5","volume":"43","author":"AD Adewumi","year":"2021","unstructured":"Adewumi AD, Maravilla JC, Alati R, Hollingworth SA, Hu X, Loveday B, et al. Pharmaceutical opioids utilisation by dose, formulation, and socioeconomic status in Queensland, Australia: a population study over 22 years. Int J Clin Pharm. 2021;43(2):328\u201339.","journal-title":"Int J Clin Pharm"},{"key":"1169_CR14","unstructured":"Australian Commission on Safety and Quality in Health Care. Opioid Analgesic Stewardship in Acute Pain Clinical Care Standard\u2014Acute care edition. Sydney: ACSQHC; 2022. https:\/\/www.safetyandquality.gov.au\/sites\/default\/files\/2022-04\/opioid-analgesic-stewardship-in-acute-pain-clinical-care-standard.pdf. Accessed 28 Mar 2024."},{"issue":"23","key":"1169_CR15","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1056\/NEJMra1807054","volume":"380","author":"KM Babu","year":"2019","unstructured":"Babu KM, Brent J, Juurlink DN. Prevention of opioid overdose. N Engl J Med. 2019;380(23):2246\u201355.","journal-title":"N Engl J Med"},{"issue":"4","key":"1169_CR16","doi-asserted-by":"publisher","first-page":"919","DOI":"10.2106\/JBJS.H.00286","volume":"91","author":"CL Kidner","year":"2009","unstructured":"Kidner CL, Mayer TG, Gatchel RJ. Higher opioid doses predict poorer functional outcome in patients with chronic disabling occupational musculoskeletal disorders. JBJS. 2009;91(4):919\u201327.","journal-title":"JBJS"},{"issue":"5","key":"1169_CR17","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1001\/jamainternmed.2013.12711","volume":"174","author":"JAG Baumblatt","year":"2014","unstructured":"Baumblatt JAG, Wiedeman C, Dunn JR, Schaffner W, Paulozzi LJ, Jones TF. High-risk use by patients prescribed opioids for pain and its role in overdose deaths. JAMA Intern Med. 2014;174(5):796\u2013801.","journal-title":"JAMA Intern Med"},{"key":"1169_CR18","unstructured":"Australian Commission on Safety and Quality in Health Care. Low back pain clinical care standard. Sydney: ACSQHC; 2022. https:\/\/www.safetyandquality.gov.au\/sites\/default\/files\/2022-08\/low_back_pain_clinical_care_standard.pdf. Accessed 28 Mar 2024."},{"issue":"5","key":"1169_CR19","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/pds.4366","volume":"27","author":"DT Coyle","year":"2018","unstructured":"Coyle DT, Pratt C-Y, Ocran-Appiah J, Secora A, Kornegay C, Staffa J. Opioid analgesic dose and the risk of misuse, overdose, and death: a narrative review. Pharmacoepidemiol Drug Saf. 2018;27(5):464\u201372.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"13","key":"1169_CR20","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1001\/jama.2011.370","volume":"305","author":"ASB Bohnert","year":"2011","unstructured":"Bohnert ASB, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305(13):1315\u201321.","journal-title":"JAMA"},{"key":"1169_CR21","doi-asserted-by":"publisher","unstructured":"Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain\u2014United States, 2022. MMWR Recomm Rep 2022;71(No. RR-3):1\u201395. https:\/\/doi.org\/10.15585\/mmwr.rr7103a1.","DOI":"10.15585\/mmwr.rr7103a1"},{"issue":"2","key":"1169_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40263-018-0499-3","volume":"32","author":"AD Adewumi","year":"2018","unstructured":"Adewumi AD, Hollingworth SA, Maravilla JC, Connor JP, Alati R. Prescribed dose of opioids and overdose: a systematic review and meta-analysis of unintentional prescription opioid overdose. CNS Drugs. 2018;32(2):101\u201316.","journal-title":"CNS Drugs"},{"key":"1169_CR23","unstructured":"Oakman J, Clune S, Stuckey R. Work-related musculoskeletal disorders in Australia. Safe Work Australia: Canberra. 2019."},{"issue":"3","key":"1169_CR24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/ajim.23083","volume":"63","author":"CJ Martin","year":"2020","unstructured":"Martin CJ, Jin C, Bertke SJ, Yiin JH, Pinkerton LE. Increased overall and cause-specific mortality associated with disability among workers\u2019 compensation claimants with low back injuries. Am J Ind Med. 2020;63(3):209\u201317.","journal-title":"Am J Ind Med"},{"issue":"10398","key":"1169_CR25","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S0140-6736(23)00404-X","volume":"402","author":"CM Jones","year":"2023","unstructured":"Jones CM, Day RO, Koes BW, Latimer J, Maher CG, McLachlan AJ, et al. Opioid analgesia for acute low back pain and neck pain (the OPAL trial): a randomised placebo-controlled trial. Lancet. 2023;402(10398):304\u201312.","journal-title":"Lancet"},{"issue":"9","key":"1169_CR26","doi-asserted-by":"publisher","first-page":"721","DOI":"10.7326\/M19-3600","volume":"173","author":"JJ Riva","year":"2020","unstructured":"Riva JJ, Noor ST, Wang L, Ashoorion V, Foroutan F, Sadeghirad B, et al. Predictors of prolonged opioid use after initial prescription for acute musculoskeletal injuries in adults: a systematic review and meta-analysis of observational studies. Ann Intern Med. 2020;173(9):721\u20139.","journal-title":"Ann Intern Med"},{"key":"1169_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.17269\/s41997-024-00882-w","volume":"115","author":"N Carnide","year":"2024","unstructured":"Carnide N, Feng G, Song C, Demers PA, MacLeod JS, Sritharan J. Occupational patterns of opioid-related harms comparing a cohort of formerly injured workers to the general population in Ontario, Canada. Can J Public Health. 2024;115:1\u201311.","journal-title":"Can J Public Health"},{"issue":"8","key":"1169_CR28","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1136\/oemed-2018-105626","volume":"76","author":"N Carnide","year":"2019","unstructured":"Carnide N, Hogg-Johnson S, Koehoorn M, Furlan AD, C\u00f4t\u00e9 P. Relationship between early prescription dispensing patterns and work disability in a cohort of low back pain workers\u2019 compensation claimants: a historical cohort study. Occup Environ Med. 2019;76(8):573\u201381.","journal-title":"Occup Environ Med"},{"issue":"2","key":"1169_CR29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/BRS.0b013e318160455c","volume":"33","author":"GM Franklin","year":"2008","unstructured":"Franklin GM, Stover BD, Turner JA, Fulton-Kehoe D, Wickizer TM. Early opioid prescription and subsequent disability among workers with back injuries: the Disability Risk Identification Study Cohort. Spine. 2008;33(2):199\u2013204.","journal-title":"Spine"},{"issue":"19","key":"1169_CR30","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1097\/BRS.0b013e318145a731","volume":"32","author":"BS Webster","year":"2007","unstructured":"Webster BS, Verma SK, Gatchel RJ. Relationship between early opioid prescribing for acute occupational low back pain and disability duration, medical costs, subsequent surgery and late opioid use. Spine. 2007;32(19):2127\u201332.","journal-title":"Spine"},{"key":"1169_CR31","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s10926-023-10138-y","volume":"34","author":"YG Tefera","year":"2024","unstructured":"Tefera YG, Gray S, Nielsen S, Gelaw A, Collie A. Impact of prescription medicines on work-related outcomes in workers with musculoskeletal disorders or injuries: a systematic scoping review. J Occup Rehabil. 2024;34:398\u2013414.","journal-title":"J Occup Rehabil"},{"issue":"7","key":"1169_CR32","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1097\/AJP.0000000000000452","volume":"33","author":"N Carnide","year":"2017","unstructured":"Carnide N, Hogg-Johnson S, Cote P, Irvin E, Van Eerd D, Koehoorn M, et al. Early prescription opioid use for musculoskeletal disorders and work outcomes: a systematic review of the literature. Clin J Pain. 2017;33(7):647\u201358.","journal-title":"Clin J Pain"},{"issue":"3","key":"1169_CR33","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1097\/JOM.0000000000000625","volume":"58","author":"RA Lavin","year":"2016","unstructured":"Lavin RA, Tao XG, Yuspeh L, Kalia N, Bernacki EJ. Relationship between opioid prescribing patterns and claim duration and cost. J Occup Environ Med. 2016;58(3):e90\u20133.","journal-title":"J Occup Environ Med"},{"issue":"4","key":"1169_CR34","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/ajim.21021","volume":"55","author":"A Dembe","year":"2012","unstructured":"Dembe A, Wickizer T, Sieck C, Partridge J, Balchick R. Opioid use and dosing in the workers\u2019 compensation setting. A comparative review and new data from Ohio. Am J Ind Med. 2012;55(4):313\u201324.","journal-title":"Am J Ind Med"},{"issue":"6","key":"1169_CR35","doi-asserted-by":"publisher","first-page":"e184050","DOI":"10.1001\/jamanetworkopen.2018.4050","volume":"1","author":"NN O\u2019Hara","year":"2018","unstructured":"O\u2019Hara NN, Pollak AN, Welsh CJ, O\u2019Hara LM, Kwok AK, Herman A, et al. Factors associated with persistent opioid use among injured workers\u2019 compensation claimants. JAMA Netw Open. 2018;1(6):e184050.","journal-title":"JAMA Netw Open"},{"key":"1169_CR36","unstructured":"Australian Bureau of Statistics (ABS). Statistics, Labour Force, Australia August 2023. Canberra, Australia: Australian Bureau of Statistics, 2023. https:\/\/www.abs.gov.au\/statistics\/labour\/employment-and-unemployment\/labour-force-australia\/latest-release#states-and-territories. Accessed 23 Mar 2024."},{"key":"1169_CR37","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1007\/s10926-018-9816-4","volume":"29","author":"A Collie","year":"2019","unstructured":"Collie A, Di Donato M, Iles R. Work disability in Australia: an overview of prevalence, expenditure, support systems and services. J Occup Rehabil. 2019;29:526\u201339.","journal-title":"J Occup Rehabil"},{"key":"1169_CR38","unstructured":"Australian Safety and Compensation Council. Type of Occurrence Classification System (TOOCS). 3rd ed revision 1 ed. Canberra: Asutralian Government: Australian Safety and Compensation Council; May 2008: 292"},{"issue":"7","key":"1169_CR39","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1097\/JOM.0000000000001900","volume":"62","author":"JR Haight","year":"2020","unstructured":"Haight JR, Sears JM, Fulton-Kehoe D, Wickizer TM, Franklin GM. Early high-risk opioid prescribing practices and long-term disability among injured workers in Washington State, 2002 to 2013. J Occup Environ Med. 2020;62(7):538\u2013600.","journal-title":"J Occup Environ Med"},{"key":"1169_CR40","unstructured":"Safe Care Victoria. Opioid conversion guidance document. 2021. https:\/\/www.safercare.vic.gov.au\/sites\/default\/files\/2021-02\/GUIDANCE_Opioid%20Conversion%20FINAL_0.pdf. Accessed 16 Aug 2023."},{"issue":"6","key":"1169_CR41","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/pds.3945","volume":"25","author":"S Nielsen","year":"2016","unstructured":"Nielsen S, Degenhardt L, Hoban B, Gisev N. A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. Pharmacoepidemiol Drug Saf. 2016;25(6):733\u20137.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"1169_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002396","volume":"14","author":"T Gomes","year":"2017","unstructured":"Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case\u2013control study. PLoS Med. 2017;14(10): e1002396.","journal-title":"PLoS Med"},{"issue":"10","key":"1169_CR43","doi-asserted-by":"publisher","first-page":"727","DOI":"10.7326\/M18-2175","volume":"169","author":"DC Throckmorton","year":"2018","unstructured":"Throckmorton DC, Woodcock J. Combined gabapentinoid and opioid use: the consequences of shifting prescribing trends. Ann Intern Med. 2018;169(10):727\u20138.","journal-title":"Ann Intern Med"},{"key":"1169_CR44","unstructured":"FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. US Food and Drug Administration. September 2017. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-urges-caution-about-withholding-opioid-addiction-medications. Accessed 20 Oct 2023."},{"issue":"2","key":"1169_CR45","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/schbul\/sbab116","volume":"48","author":"AG Szmulewicz","year":"2022","unstructured":"Szmulewicz AG, Bateman BT, Levin R, Huybrechts KF. Risk of overdose associated with co-prescription of antipsychotics and opioids: a population-based cohort study. Schizophr Bull. 2022;48(2):405\u201313.","journal-title":"Schizophr Bull"},{"issue":"2","key":"1169_CR46","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/ADM.0000000000000457","volume":"13","author":"MA Coe","year":"2019","unstructured":"Coe MA, Lofwall MR, Walsh SL. Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med. 2019;13(2):93\u2013103.","journal-title":"J Addict Med"},{"issue":"3","key":"1169_CR47","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/00045391-200105000-00006","volume":"8","author":"BH McCarberg","year":"2001","unstructured":"McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther. 2001;8(3):181\u20136.","journal-title":"Am J Ther"},{"issue":"4","key":"1169_CR48","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/00002508-200207001-00002","volume":"18","author":"CE Inturrisi","year":"2002","unstructured":"Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain. 2002;18(4):S3\u201313.","journal-title":"Clin J Pain"},{"issue":"5","key":"1169_CR49","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1526-4637.2005.00057.x","volume":"6","author":"AK Matsumoto","year":"2005","unstructured":"Matsumoto AK, Babul N, Ahdieh H. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo-and active-controlled phase III trial. Pain Med. 2005;6(5):357\u201366.","journal-title":"Pain Med"},{"key":"1169_CR50","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/S0025-6196(11)60749-0","volume":"84","author":"CE Argoff","year":"2009","unstructured":"Argoff CE, Silvershein DI. A comparison of long-and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. Mayo Clin Proc. 2009;84:602\u201312.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"1169_CR51","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/bcp.13556","volume":"84","author":"S Lalic","year":"2018","unstructured":"Lalic S, Gisev N, Bell JS, Korhonen MJ, Ilom\u00e4ki J. Predictors of persistent prescription opioid analgesic use among people without cancer in Australia. Br J Clin Pharmacol. 2018;84(6):1267\u201378.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1169_CR52","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/j.1532-2149.2011.00018.x","volume":"16","author":"K Svendsen","year":"2012","unstructured":"Svendsen K, Skurtveit S, Romundstad P, Borchgrevink P, Fredheim O. Differential patterns of opioid use: defining persistent opioid use in a prescription database. Eur J Pain. 2012;16(3):359\u201369.","journal-title":"Eur J Pain"},{"key":"1169_CR53","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1146\/annurev.clinpsy.121208.131413","volume":"6","author":"DS Nagin","year":"2010","unstructured":"Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol. 2010;6:109\u201338.","journal-title":"Annu Rev Clin Psychol"},{"issue":"1","key":"1169_CR54","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/ejp.2163","volume":"28","author":"HH Nestvold","year":"2024","unstructured":"Nestvold HH, Skurtveit SS, Hamina A, Hjellvik V, Odsbu I. Socioeconomic risk factors for long-term opioid use: a national registry-linkage study. Eur J Pain. 2024;28(1):95\u2013104.","journal-title":"Eur J Pain"},{"issue":"4","key":"1169_CR55","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/aas.12281","volume":"58","author":"K Svendsen","year":"2014","unstructured":"Svendsen K, Fredheim OM, Romundstad P, Borchgrevink PC, Skurtveit S. Persistent opioid use and socio-economic factors: a population-based study in Norway. Acta Anaesthesiol Scand. 2014;58(4):437\u201345.","journal-title":"Acta Anaesthesiol Scand"},{"issue":"5","key":"1169_CR56","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/pds.3931","volume":"25","author":"L Degenhardt","year":"2016","unstructured":"Degenhardt L, Gisev N, Cama E, Nielsen S, Larance B, Bruno R. The extent and correlates of community-based pharmaceutical opioid utilisation in Australia. Pharmacoepidemiol Drug Saf. 2016;25(5):521\u201338.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1169_CR57","unstructured":"Australian Bureau of Statistics (ABS). Postal area, indexes, SEIFA 2011. Census of population and housing: socio-economic indexes for areas (SEIFA), Australia, 2011. Canberra: Australian Bureau of Statistics, 2013."},{"key":"1169_CR58","unstructured":"Australian Bureau of Statistics (ABS). 2006 RA from 2006 POA correspondence. Australian standard geographical classification (ASGC) remoteness area correspondences. Canberra: Australian Bureau of Statistics, 2011."},{"key":"1169_CR59","unstructured":"Australian Bureau of Statistics. Australian standard classification of occupations. Canberra: Australian Bureau of Statistics; 1997."},{"key":"1169_CR60","volume-title":"Stata statistical software: release 17","author":"StataCorp.","year":"2021","unstructured":"StataCorp. Stata statistical software: release 17. College Station: StataCorp LLC; 2021."},{"key":"1169_CR61","unstructured":"Safe Work Australia. Comparison of workers' compensation arrangments in Australia and New Zealand 2021. 28th Edition. Safe Work Australia. https:\/\/www.safeworkaustralia.gov.au\/sites\/default\/files\/2022-10\/comparison_of_workers_compensation_arrangements_in_australia_and_new_zealand_2021_swa_edits.pdf. Accessed 28 Mar 2024."},{"issue":"12","key":"1169_CR62","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1097\/JOM.0000000000000557","volume":"57","author":"XG Tao","year":"2015","unstructured":"Tao XG, Lavin RA, Yuspeh L, Weaver VM, Bernacki EJ. Is early prescribing of opioid and psychotropic medications associated with delayed return to work and increased final workers\u2019 compensation cost? J Occup Environ Med. 2015;57(12):1315\u20138.","journal-title":"J Occup Environ Med"},{"issue":"2","key":"1169_CR63","doi-asserted-by":"publisher","first-page":"307","DOI":"10.5664\/jcsm.6470","volume":"13","author":"MJ Sateia","year":"2017","unstructured":"Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307\u201349.","journal-title":"J Clin Sleep Med"},{"issue":"3","key":"1169_CR64","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1136\/oemed-2019-105995","volume":"77","author":"C Orchard","year":"2020","unstructured":"Orchard C, Carnide N, Mustard C, Smith PM. Prevalence of serious mental illness and mental health service use after a workplace injury: a longitudinal study of workers\u2019 compensation claimants in Victoria, Australia. Occup Environ Med. 2020;77(3):185\u20137.","journal-title":"Occup Environ Med"},{"key":"1169_CR65","doi-asserted-by":"crossref","unstructured":"Ferreira GE, Abdel-Shaheed C, Underwood M, Finnerup NB, Day RO, McLachlan A, et al. Efficacy, safety, and tolerability of antidepressants for pain in adults: overview of systematic reviews. BMJ. 2023;380:e072415.","DOI":"10.1136\/bmj-2022-072415"},{"key":"1169_CR66","doi-asserted-by":"crossref","unstructured":"Tefera YG, Nielsen S, Gray S, Di Donato M, Sheehan LR, Collie A. Psychotropic medicine utilisation in Australian workers with workers\u2019 compensation claims for back and neck musculoskeletal disorders or injuries. \"under review\". 2025.","DOI":"10.1002\/bcp.70426"},{"issue":"5","key":"1169_CR67","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1136\/oemed-2023-109369","volume":"81","author":"S Mathieson","year":"2024","unstructured":"Mathieson S, Collie A, Maher CG, Abdel Shaheed C, Xia T, Gilbert S, et al. Secular trends in gabapentinoid dispensing by compensated workers with low back pain: a retrospective cohort study. Occup Environ Med. 2024;81(5):245\u201351.","journal-title":"Occup Environ Med"},{"key":"1169_CR68","doi-asserted-by":"publisher","first-page":"100579","DOI":"10.1016\/j.lanepe.2022.100579","volume":"27","author":"J Ashworth","year":"2023","unstructured":"Ashworth J, Bajpai R, Muller S, Bailey J, Helliwell T, Harrisson SA, et al. Trends in gabapentinoid prescribing in UK primary care using the Clinical Practice Research Datalink: an observational study. Lancet Reg Health Eur. 2023;27:100579.","journal-title":"Lancet Reg Health Eur"},{"issue":"4","key":"1169_CR69","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/bcp.15984","volume":"90","author":"L Durand","year":"2024","unstructured":"Durand L, O\u2019Kane A, Tierney J, Cronly M, Bennett KE, Kavanagh Y, et al. Gabapentinoids in Ireland 2010 to 2020: an observational study of trends in gabapentinoid prescribing, law enforcement drug seizures and postmortem toxicology. Br J Clin Pharmacol. 2024;90(4):987\u201395.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"1169_CR70","doi-asserted-by":"publisher","first-page":"e694","DOI":"10.1097\/JOM.0000000000002344","volume":"63","author":"RA Lavin","year":"2021","unstructured":"Lavin RA, Liu C, Yuspeh L, Kalia N, Leung N, Tsourmas NF, et al. Trends in the utilization and dose of gabapentinoids in combination with opioids in an injured worker population between 2008 and 2018. J Occup Environ Med. 2021;63(10):e694\u2013700.","journal-title":"J Occup Environ Med"},{"issue":"8","key":"1169_CR71","doi-asserted-by":"publisher","first-page":"e2328159","DOI":"10.1001\/jamanetworkopen.2023.28159","volume":"6","author":"N Gisev","year":"2023","unstructured":"Gisev N, Buizen L, Hopkins RE, Schaffer AL, Daniels B, Bharat C, et al. Five-year trajectories of prescription opioid use. JAMA Netw Open. 2023;6(8):e2328159.","journal-title":"JAMA Netw Open"},{"key":"1169_CR72","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1093\/pm\/pnae071","volume":"25","author":"M Jung","year":"2024","unstructured":"Jung M, Xia T, Ilom\u00e4ki J, Pearce C, Aitken A, Nielsen S. Predictors of persistent opioid use in Australian primary care: a retrospective cohort study, 2018\u20132022. Pain Med. 2024;25:748\u201357.","journal-title":"Pain Med"},{"issue":"9","key":"1169_CR73","doi-asserted-by":"publisher","first-page":"e515","DOI":"10.1097\/JOM.0000000000001961","volume":"62","author":"A Asfaw","year":"2020","unstructured":"Asfaw A, Quay B, Chang C-C. Do injured workers receive opioid prescriptions outside the workers\u2019 compensation system? The case of private group health insurances. J Occup Environ Med. 2020;62(9):e515\u201322.","journal-title":"J Occup Environ Med"},{"issue":"9","key":"1169_CR74","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jama.2012.234","volume":"307","author":"KH Seal","year":"2012","unstructured":"Seal KH, Shi Y, Cohen G, Cohen BE, Maguen S, Krebs EE, et al. Association of Mental health disorders with prescription opioids and high-risk opioid use in US veterans of Iraq and Afghanistan. JAMA. 2012;307(9):940\u20137.","journal-title":"JAMA"},{"issue":"4","key":"1169_CR75","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/bcp.15996","volume":"90","author":"T Xia","year":"2024","unstructured":"Xia T, Picco L, Buchbinder R, Haas R, Nielsen S. Association of state-level prescription drug monitoring program implementation with opioid prescribing transitions in primary care in Australia. Br J Clin Pharmacol. 2024;90(4):1162\u201372.","journal-title":"Br J Clin Pharmacol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01169-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01169-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01169-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:02:31Z","timestamp":1767859351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01169-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1169"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01169-5","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"9 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yonas Tefera is funded by Monash Graduate Research Scholarship for his PhD study. Professor Alex Collie is supported by an Australian Research Council Future Fellowship (#FT190100218). Professor Suzanne Nielsen is supported by a National Health and Medical Research Council Career Development Fellowship (#1163961). Dr. Shannon Gray is supported by an Australian Research Council Discovery Early Career Research Award (#DE220100456). Dr. Michael Di Donato is supported by a National Health and Medical Research Council Centre for Research Excellence (APP1171459).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Y.G.T. conceived and designed the study, prepared the data, performed the analysis, interpreted the results, and wrote the initial draft of the manuscript. A.C., S.N., and S.G. were involved in the conception, design, supervision, interpretation, and critical review of the manuscript. M.D.D. led the data acquisition, data preparation, and critical review of the manuscript. All authors reviewed and approved the final manuscript for submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contribution"}},{"value":"All authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Data used in this study are not available for distribution by the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statements"}},{"value":"Available on request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent\u00a0for participation"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The study was approved by the Monash University Human Research Ethics Committee (Project ID: 30718).","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}